Two nonsynonymous polymorphisms in the coding region of the CX 3 CR1 gene were initially identified as possibly being associated with more-rapid disease progression in HIV-1-infected adults [5] : a GrA polymorphism at nt 745, which changes valine to isoleucine at aa 249 (V/I249) in the sixth transmembrane domain of the CX 3 CR1 protein, and a CrT polymorphism at nt 849, which changes threonine to methionine at aa 280 (T/M280) in the seventh transmembrane domain of the CX 3 CR1 protein. It has been proposed that reduced CX 3 CR1 expression and fractalkine binding in individuals with the CX 3 CR1 M/M280 genotype could compromise normal immune responses, leading to accelerated progression of HIV-1 disease [5] . However, subsequent studies failed to observe such associations between these polymorphisms and HIV-1 disease in adults [6] [7] [8] . Recently, Faure et al. [9] reported that HIV-1-infected persons homozygous for CX 3 CR1 M280 progressed to AIDS more rapidly than did those with other genotypes. Moreover, they suggested that this deleterious effect predicted that a cohort of seropreva-lent adults would be depleted of M280 carriers, because these patients would have been at a higher risk for death before recruitment to a study. Faure et al. [5] also studied the impact of the V/I249 polymorphism on disease progression but found no association. Brumme et al. [10] found a trend toward an association of the I249-T280 and I249-M280 haplotypes with early immunological failure in HIV-1-infected adults.
The expression of CX 3 CR1 and its ligand, fractalkine, is increased during HIV-1 infection and is reduced on treatment with highly active antiretroviral therapy (HAART) [11] , suggesting that they play an important role in directing the immune response against HIV-1. Fractalkine expression has been reported to be up-regulated in the brains of patients with AIDS, and fractalkine produced during interactions between monocytes and HIV-1-infected macrophages is thought to play a role in HIV-1-associated dementia by regulating the trafficking of monocytes in brain parenchyma [12] [13] [14] [15] .
On the basis of the available information on fractalkine and CX 3 CR1, we hypothesized that decreased expression of CX 3 CR1, due to the presence of specific CX 3 CR1 genetic variations, would lead to inefficient fractalkine-CX 3 CR1 binding that could interfere with the immunologic response to HIV-1 and, thus, impact overall disease progression and central nervous system (CNS) impairment. We have previously shown in a cohort of HIV-1-infected children that the CCR5 wild type (wt)/D32 and CCR5 59029G/A genotypes were significant predictors of HIV-1-related disease progression [16] . We believed that the impact of genetic variants of CX 3 CR1 might be more easily observed in this cohort of children because of the more-rapid disease progression and higher frequency of CNS impairment associated with HIV-1 infection in children, compared with that in adults.
PATIENTS AND METHODS

Patient populations.
The patients studied formed a cohort of seroprevalent children with symptomatic HIV-1 infection who participated in randomized, double-blind, multicenter Pediatric AIDS Clinical Trials Group (PACTG) cohorts 152 (n p 462) [17] or 300 ( ) [18] , which were designed (1) n p 593 to compare the effects of monotherapy with either zidovudine (ZDV) or didanosine (ddI) versus the effects of combination therapy with ZDV plus ddI and (2) to compare the effects of combination therapy with ZDV plus lamivudine (3TC) versus the effects of ddI monotherapy and of combination therapy with ZDV plus ddI, respectively. Of the 1055 children studied, 576 (55%) were female. The median age was 2.4 years (10th and 90th percentiles, 0.5 and 9.4 years, respectively). Of the 1055 children, 320 (30%) were followed for !12 months, 451 (43%) were followed for 12-23 months, 198 (19%) were followed for 24-35 months, and 86 (8%) were followed for у36 months. A total of 229 (22%) were identified as having HIV-1-related disease progression during the course of the 2 studies. Details of the characteristics of children, eligibility criteria, study end points, disease progression, and neuropsychological tests used have been described elsewhere [16] [17] [18] . Informed consent was obtained from guardians of the study participants. This study followed the human experimentation guidelines of the US Department of Health and Human Services and the University of California, San Diego review board.
Genotyping. CX 3 CR1 V/I249 and T/M280 genotyping was performed by real-time polymerase chain reaction (PCR) using melting curve analysis (LightCycler). One set of primers and 2 sets of fluorescence-labeled hybridization probes were used in this assay; primer sequences were as follows: forward primer, 5 -TTGGCTTCCTACTCCC; reverse primer, 5 -TCCCATACAGG-TGGTAA. For detection of the CX 3 CR1 745G/A polymorphism (V/I249), the sensor and anchor probe sequences were as follows: 5 -TAACGTTGTAGGGTGTCCAGA-fluorescein isiothiocyanate (FITC) and LCR640-AGGAAAAACACGATGACCACCPhos; the melting curve was analyzed in channel F2, with the G/ G and A/A genotypes having melting-temperature values of 63ЊC and 59ЊC, respectively. For detection of the CX 3 CR1 849C/T polymorphism (T/M280), the sensor and anchor probe sequences were LCR705-TGAGACGGTTGCATTTAGCC-Phos and 5 -GGC-TGGCCCTCAGTGTG-FITC; the melting curve was analyzed in channel F3, with C/C and T/T genotypes having meltingtemperature values of 64ЊC and 55ЊC, respectively. Probes were hybridized to the complementary strand of target DNA, and underlined C nucleotides in the above sequences show the sites of polymorphisms; the amplicon length was 336 nt. The specificity of genotyping assays was confirmed by conventional PCR-restriction fragment length polymorphism analysis [19] .
Statistical methods. Analysis of variance and analysis of covariance were used to compare markers of disease status at trial entry. The Mantel-Haenszel test, stratified by age, age squared, and race/ethnicity, was used to evaluate differences in genotype and allele frequencies. Analyses of progression to a study end point were performed using Kaplan-Meier estimates and proportional-hazards models stratified by study and randomized treatment. Analyses that stratified further by race/ethnicity gave very similar results; therefore, data are presented without specific reference to race/ethnicity.
RESULTS
Distribution
of CX 3 CR1 genotypes and haplotypes. Because the impact of specific polymorphisms in CX 3 CR1 on HIV-1-associated disease could vary with the diverse genetic backgrounds present in different racial/ethnic groups, we examined the distribution of genotypes within our pediatric cohort. Table  1 ) in the whole cohort ( ) ( figure 1A ) P p .050 P p .009 and in the subset with the CCR5 wt/wt genotype ( ) P ! .001 (figure 1B). In both the whole cohort and the CCR5 wt/wt subset, there was little difference in the rate of disease progression between children carrying the V/I249 genotype and those carrying the V/V249 genotype. The effect of the I/I249 genotype persisted in a multivariate analysis that adjusted for the CCR5 wt/D32, CCR5 59029G/A, and CX 3 CR1 T/M280 polymorphisms (table 2) .
There were no significant effects of CX 3 CR1 280 genotype on HIV-1-related disease progression in the whole cohort (P p .22) (figure 1C) or in the subset with the CCR5 wt/wt genotype ( ) ( figure 1D ). There was also no significant as-P p .09 sociation found for CX 3 CR1 280 genotype in multivariate analysis (table 2) . ) in the whole P p .11 cohort ( ) (figure 2A); this association was marginally P p .14 significant in the subset with the CCR5 wt/wt genotype (P p ) ( figure 2B ). The trend in the overall study population .051 persisted in multivariate analyses adjusted for the CCR5 wt/ D32, CCR5 59029G/A, and CX 3 CR1 T/M280 polymorphisms but was not statistically significant (data not shown).
The CX 3 CR1 M/M280 genotype was associated with greater CNS impairment in the whole cohort ( ) ( figure 2C ) P p .014 and in children with the CCR5 wt/wt genotype ( ) (fig-P p .009 ure 2D). However, these analyses should be viewed cautiously, because the number of children with the CX 3 CR1 M/M280 genotype was small (i.e., only 5 children, including 2 whose disease progressed, had the M/M280 genotype).
CX 3 CR1 haplotypes and HIV-1-related disease progression and CNS impairment. We next examined the impact of presence of specific CX 3 CR1 haplotypes on disease progression. Children with the V249-T280 haplotype were less likely to develop disease and had a slower rate of disease progression than did children without this haplotype ( ) (figure 3A). The P p .005 improved outcome for the cohort of children with the V249-T280 haplotype was further supported in a multivariate analysis adjusted for CCR5 and CCR5 59029 genotype (RH, 0.43 [95% CI, 0.25-0.73]; ) (table 2) . In contrast, children with P p .002 the I249-T280 haplotype had shorter progression-free survival, in both the whole cohort ( ) ( figure 3B ) and the subset P p .018 with the CCR5 wt/wt genotype ( ); this association with P p .008 disease progression was also maintained in a multivariate analysis adjusted for the CCR5 wt/D32 and CCR5 59029G/A poly- morphisms (table 2) . There was no significant association between I249-M280 haplotype and progression-free survival in the whole cohort ( ) ( figure 3C ) or in the subset with P p .22 the CCR5 wt/wt genotype ( ), in both univariate and P p .09 multivariate analyses (table 2) .
Children with the V249-T280 haplotype had a lower risk of a CNS end point ( ) ( figure 3D ), which persisted in P p .052 children with the CCR5 wt/wt genotype ( ). The as-P p .015 sociation was marginal in multivariate analyses adjusted for CCR5 and CCR5 59029 genotype (RH, 0.47 [95% CI, 0.20-
1.08];
). There were no significant differences in CNS P p .075 impairment in children with versus without the I249-T280 haplotype ( ) or in those with versus without the I249-M280 P p .11 haplotype ( ), in the whole cohort or in the subset with P p .96 the CCR5-wt/wt genotype, in both univariate and multivariate analyses (data not shown).
Influence of the CX 3 CR1 I/I249 genotype and V249-T280 haplotype on HIV-1 disease progression after adjusting for CD4 + lymphocyte count and HIV-1 RNA load at baseline. Because CD4 + lymphocyte count and percentage and plasma HIV-1 RNA load are the strongest predictors of risk of disease progression in children as well as adults [20- + lymphocyte count and plasma HIV-1 RNA load during follow-up by including these as timedependent variables in proportional-hazards models. Of note, the impact of the CX 3 CR1 I/I249 genotype and V249-T280 haplotype remained significantly associated with disease progression and development of neurocognitive impairment, whereas the CCR5 wt/D32 and CCR5 59029A/A genotypes lost significance in the models (table 3) .
DISCUSSION
An increasing body of literature supports the concept that host and microbial genetics are important determinants of infection and disease outcome. Viruses use chemokines and their receptors as their own receptors, apparently in an attempt to evade the immune system. With the identification of chemokine receptors as coreceptors for HIV-1 infection, mutations in genes encoding these receptors and their natural ligands have been shown to modify the risk of HIV-1 infection and disease progression. To date, most genetic variants identified as having an impact on HIV-1-related disease progression have their effect through modification of the ability of the virus to bind to and efficiently infect susceptible cells. Although CX 3 CR1 has been identified as a potential coreceptor for HIV-1, it appears to play a role in viral attachment and entry that is minor compared with that of the dominant coreceptors, CCR5 and CXCR4. Thus, we believe that the impact of polymorphisms in CX 3 CR1 on HIV-1 disease progression is more likely to be through its fundamental role in directing inflammatory cells to specific sites of infection to initiate innate and adaptive immunity [24] .
The impact of polymorphisms in CX 3 CR1 on disease progression in HIV-1-infected adults remains controversial. In at least 2 HIV-1-infected cohorts, no association was observed between the CX 3 CR1 M280 allele and disease progression [6, 7] . In a third study, similar frequencies of CX 3 CR1 249 and 280 genotypes were observed in patients with rapid progression and those without progression [8] . In contrast to the findings in these recent studies of adults-but in agreement with those in studies by Faure et al. [5, 9] -our findings strongly indicate that genetic variants that alter the expression of functional CX 3 CR1 can profoundly influence the risk and rate of HIV-1-related disease in children. Moreover, in multivariate analyses, our data indicate that a specific CX 3 CR1 genotype and haplotype strongly predict both disease progression and CNS impairment independently of markers such as CD4 + lymphocyte count and plasma HIV-1 RNA load, as well as other genetic variants, including the CCR5 wt/D32, CCR5 59029G/A, and CX 3 CR1 T/M280 polymorphisms.
In the present study, children with the wild-type CX 3 CR1 V/ V249 genotype-which has been associated with greater bind-ing to fractalkine, compared with that in individuals with the I/I249 genotype [5] -experienced slower HIV-1 disease progression than did children with the I/I249 genotype; however, the disease progression in V/I249 heterozygotes was similar to that in children with the V/V249 genotype. A similar trend was observed by Brumme et al. [10] ; however, in their study that included V/I249 heterozygotes, this effect was only marginally significant ( ). Similarly, the T280 allelic variant, also P p .07 associated with enhanced binding of fractalkine, was associated with slower disease progression, compared with the M280 allele. Furthermore, Faure et al. [5] found that CX 3 CR1 expression was not significantly different among haplotypes; however, fractalkine binding affinity was highest in the V249-T280 haplotype, compared with the I249-T280 and I249-M280 haplotypes.
The strength of the impact of the CX 3 CR1 I/I249 genotype on disease progression in HIV-1-infected children is further supported by the multivariate analyses including the CCR5 wt/ D32, CCR5 59029G/A, and CX 3 CR1 T/M280 polymorphisms, demonstrating that the CX 3 CR1 249-I/I genotype and the V249-T280 haplotype have a significant impact on the rate of disease progression. These findings contrast with those of earlier studies of adults, conducted by Faure et al. [5] , which failed to find an impact of the V/I249 polymorphism on disease progression. It is unclear why Faure et al. did not observe a significant impact of CX 3 CR1 polymorphisms in their cohort; one possible reason is that their study sample consisted of seroprevalent adults, which suggests that the impact of these polymorphisms may be greater in children than in adults. This explanation is unlikely, however, because Brumme et al. [10] observed trends for associations of the I249-T280 and I249-M280 haplotypes with immunological failure in HIV-1-infected adults. Their study, however, did not evaluate the impact of the V/I249 polymorphismindependent of the T/M280 polymorphism-on HIV-1-related disease progression.
In addition to having an important influence on overall HIV-1-related disease, the polymorphisms in CX 3 CR1 are also, on the basis of our observations, associated with CNS impairment in children. In children with the CCR5 wt/wt genotype, we observed a significant association between the presence of the CX 3 CR1 I/I249 genotype and an increased risk for neurocognitive disease in univariate analysis, with a similar trend present in multivariate analysis. The same trend of increased risk was observed in children with the M/M280 genotype, albeit with a small number of children. Thus, because CX 3 CR1 is normally expressed in higher quantities in the brain than in other organs [4] and because CX 3 CR1/fractalkine expression is affected by HIV-1 infection [11] [12] [13] [14] [15] , it would appear that genetic variants producing less CX 3 CR1 may place HIV-1-infected children at increased risk for CNS impairment. Haplotype data provide additional support for the role of CX 3 CR1 variants in the development of CNS impairment, with children with the V249-T280 haplotype experiencing less than one-half the risk for development of CNS disease seen in children without the V249-T280 haplotype.
At baseline, no effects of CX 3 CR1 polymorphisms were observed in our cohort, suggesting that these polymorphisms exert their effects during later stages of HIV-1 infection. These findings are consistent with those of the study by Faure et al. [5] , in which the divergence of disease progression among CX 3 CR1 genotypic groups was observed only after 30 months of infection. These observations further support the hypothesis that the effects of polymorphisms in CX 3 CR1 are on the recruitment of immunomodulatory cells to sites of HIV-1 infection and have the broadest impact on the ability of the immune system to sustain suppression of the virus. The hypothesis that reduced CX 3 CR1 expression and fractalkine binding in individuals with the I/I249 and M/M280 genotypes can compromise normal immune responses is also supported by recent data demonstrating that increased expression of CX 3 CR1 on CD8
+ and CD4 + lymphocytes is associated with disease progression in HIV-infected adults [24] . Interestingly, CX 3 CR1 appears to be the main homing receptor of CD4 + and CD8 + lymphocytes, since the expression of most other chemokine receptors is reduced with advancing HIV-1-related disease. The importance of CX 3 CR1 in cell trafficking is further supported by the expanding list of other diseases associated with inflammation that are influenced by CX 3 CR1 expression, such as coronary artery [19, 25, 26] and renal [27] inflammatory diseases.
Of particular note, the disease-progression impact of the CX 3 CR1 I/I249 genotype and the protective impact of the V249-T280 haplotype on HIV-1-related disease progression were independent of CD4 + lymphocyte count and plasma HIV-1 RNA load, both at baseline and follow-up. These findings suggest that CX 3 CR1 polymorphisms provide additional information regarding the control of HIV-1, independent of CD4 + lymphocyte count. The mechanism for the effect may be through its chemotactic function in recruitment of lymphocytes, monocytes, and NK cells to the site of HIV-1 infection. In this regard, Combadiere et al. [24] have demonstrated that CX 3 CR1 plays an important role in homing and antiviral potency of CD8 + effector-memory T lymphocytes in HIV-1-infected patients.
Our results also demonstrate that the prevalence of the CX 3 CR1 V/I249 and T/M280 polymorphisms differ significantly by race/ethnicity. The I249 and M280 alleles and haplotypes were most prevalent in non-Hispanic white children and least common in non-Hispanic black children. Thus, the impact of these polymorphisms on HIV-1 disease may be greatest in non-Hispanic white children. Most other studies have included nonHispanic white adults. It is important to note, therefore, that we found no significant differences by race/ethnicity in the associations between CX 3 CR1 polymorphisms and disease progression or development of CNS impairment. Also, in contrast to obser-vations by Faure et al. [5] , who found no CX 3 CR1 polymorphisms among 45 West African individuals, African American children in our study had the same genotypic variants as did non-Hispanic white and Hispanic children, albeit at lower frequencies.
To our knowledge, ours is the first study to examine the impact of genetic variants of CX 3 CR1 on HIV-1 infection in children. Compared with adults, children have more-rapid HIV-1 disease progression, higher absolute counts of CD4 + lymphocytes, higher HIV-1 RNA loads, and more neurocognitive impairment. Thus, the impact of CX 3 CR1 polymorphisms on HIV-1 infection in children could be fundamentally different from that in adults. Additionally, although our cohort was a seroprevalent population, the timing of infection for this perinatally infected cohort is known and is not affected by the widely disparate timing and routes of infection that may be present in adult cohorts. Also, whereas antiretroviral therapy was uncontrolled in previous cohorts, treatment was well documented in the cohort in the present study. Moreover, although the children in our cohort received 1 or 2 nucleoside reverse-transcriptase inhibitors, these regimens were standardized for each participant, and we did not find any dependence of the reported associations on the type of antiretroviral therapy received. Thus, our findings indicate that the CX 3 CR1 I/I249 genotype is associated with more-rapid disease progression and CNS impairment in HIV-1-infected children and that the presence of the V249-T280 haplotype is associated with improved clinical outcome.
